Request Trial

Marisa Woutersen

Key details

Marisa Woutersen is a senior reporter for Life Sciences Intellectual Property Review and World IP Review. She largely covers intellectual property developments across the global life sciences sector, including pharmaceuticals, biotechnology, medtech, AI, M&A and regulation.

Since joining Newton Media in 2023, Marisa has reported across a wide range of topics, from the rise of generative AI and its impact on the creative industries to the crossover between intellectual property and sport, including issues affecting athletes, as well as global pharmaceutical disputes, vaccine technology, access to medicines and life sciences M&A.

She has reported live from court and regularly travels to international conferences, where she interviews lawyers, business leaders and other key industry figures.

Marisa holds a Master’s in International Law and a BA in Politics and International Relations from the University of Sussex, and is currently completing her NCTJ Diploma in Journalism.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 456

Articles by Marisa Woutersen

Troutman Pepper Locke exodus sees teams leave in Chicago and London
Careers
Troutman Pepper Locke exodus sees teams leave in Chicago and London
Two large teams leave Locke Lord following Troutman Pepper merger | Buchanan opens Chicago office with a large life sciences group | Shoosmiths adds team in London to expand brand-focused IP services.   7 January 2025
Ex-Baker McKenzie patent litigation head joins Morgan Lewis in Germany
Careers
Ex-Baker McKenzie patent litigation head joins Morgan Lewis in Germany
New partner brings technical background in computer science and more than a decade experience in patent litigation | Expertise in tech, engineering, chemical, and life sciences sectors.   7 January 2025
Mitsubishi Tanabe takes on Indian generic drugmaker’s ALS application
Americas
Mitsubishi Tanabe takes on Indian generic drugmaker’s ALS application
The Japanese pharma company files complaint against Lupin Pharmaceuticals | Suit alleges patent infringement over the company’s proposed generic version of a key ALS drug.   2 January 2025
Americas
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Massachusetts medical research company is awarded damages following a jury verdict that found a Japanese pharma had infringed on its patent | Patent relates to Duchenne muscular dystrophy treatment.   24 December 2024
Americas
LSPN launches its first-ever US awards to celebrate life sciences leaders
LSIPR’s key event series to host its inaugural ceremony next year in Boston | Spotlight on top innovators and firms in life sciences IP | Gala to honour contributions across 21 categories with 15 judges.   17 December 2024
Americas
How Inhibrx defended a $450m damages suit
A Delaware jury unanimously sided with Sanofi-owned biotech Inhibrx, clearing it of trade secrets misappropriation claims. Amy Candido of Wilson Sonsini shares insights into the defence strategy that led to the win.   16 December 2024
Americas
Foley & Lardner adds litigation and transaction expert in New York
Firm expands its Mechanical & Electromechanical Technologies Practice with latest addition | Partner brings nearly two decades of experience in IP strategy, litigation, and transactions | Experience in biotechnology, medical devices, and blockchain.   12 December 2024
Americas
‘A marathon and a sprint at the same time’: How we won $452m damages
With 27 witnesses, plus both patent infringement and misappropriation claims, lead counsel for Insulet Alexandra Valenti and Scott Bluni share ‘a milestone’ in DTSA case law.   12 December 2024
Americas
Trump’s return sparks calls for pro-patent agenda
As President-elect Donald Trump prepares for his second term, the life sciences industry is calling for predictability, finds Marisa Woutersen.   5 December 2024
Americas
Amgen faces pushback over bid to narrow patent scope
German biotech asks federal judge to reject Amgen’s efforts to narrow scope of a key patent in ongoing dispute | Patent relates to Lindis' cancer immunotherapy treatment | Lindis calls on court to uphold the broader interpretation and claims Amgen’s attempt to narrow is inconsistent with the patent's history.   3 December 2024

Not finding what you're looking for, please try resetting your applied search and filters,
or try the full site search.